3-丁烯酸乙烯基酯 | 19480-15-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-丁烯酸乙烯基酯
• 英文名称: vinyl 3-butenoate
• 英文别名: ethenyl but-3-enoate
• CAS: 19480-15-0
• 化学式: C₆H₈O₂
• 分子量: 112.128
• InChiKey: PROZFBRPPCAADD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916190090

反应信息

• 作为反应物：
  描述：

  3-丁烯酸乙烯基酯 、 苯硫酚 在 pseudomonas lipase 作用下， 以 甲苯 为溶剂， 反应 72.0h， 以50%的产率得到1-(phenylthio)ethyl 3-butenoate
  参考文献：
  名称：

  Synthesis of α-Arylthioalkyl Esters: The Addition Reactions of Vinyl Esters with Arylthiols Catalyzed by Lipase

  摘要：

  Abstractα‐Arylthioalkyl esters can be prepared by the addition reactions of vinyl esters with arylthiols in the presence of Pseudomonas lipase (PSL) as catalyst. In the toluene, the reaction mixtures were stirred at 60 °C for three days, the chemical yields up to 85% were obtained.

  DOI：

  10.1002/jccs.199700012
• 作为产物：
  描述：

  乙酸乙烯酯 、 乙烯基乙酸 在 三氟化硼乙醚 、 对苯二酚 作用下， 生成 3-丁烯酸乙烯基酯
  参考文献：
  名称：

  Synthesis of vinyl esters of unsaturated acids

  摘要：

  DOI：

  10.1007/bf00911853

文献信息

• [EN] RAF-DEGRADING CONJUGATE COMPOUNDS<br/>[FR] COMPOSÉS CONJUGUÉS DE DÉGRADATION DE RAF
  申请人：QUARTZ THERAPEUTICS INC

  公开号：WO2018200981A1

  公开（公告）日：2018-11-01

  The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF- Degrading Conjugate Compound.

  本公开提供了用于治疗癌症和其他与RAF相关疾病的RAF降解共轭化合物。还提供了药物组合物、治疗方法和包含RAF降解共轭化合物的试剂盒。
• [EN] NANOPARTICLE, LIPOSOMES, POLYMERS, AGENTS AND PROTEINS MODIFIED WITH REVERSIBLE LINKERS<br/>[FR] NANOPARTICULES, LIPOSOMES, POLYMÈRES, AGENTS ET PROTÉINES MODIFIÉS AVEC DES LIEURS RÉVERSIBLES
  申请人：UNIV NORTH CAROLINA

  公开号：WO2012112689A1

  公开（公告）日：2012-08-23

  Pharmaceutical, chemical and biological agents containing a reversible disulfide linker are described. These agents can also be covalently bound or contained in delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain an agent having a reversible disulfide linker and to vehicles that are covalently linked to the agent containing a reversible disulfide linker. The modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting while the reversibility of the linker can leave the agent to which it is attached free from residual chemical groups after being reduced.

  描述了含有可逆二硫键的药物、化学物质和生物制剂。这些制剂也可以共价结合或包含在传递载体中，以将制剂传递到所需的靶标或区域。还描述了含有可逆二硫键的制剂的传递载体，以及与含有可逆二硫键的制剂共价结合的载体。本文描述的修饰可以改变制剂和载体的性质，从而提供所需的溶解性、稳定性、疏水性和靶向性，而连接物的可逆性可以使其附着的制剂在还原后不受残留化学基团的影响。
• PERFUME SYSTEMS
  申请人：Smets Johan

  公开号：US20110308556A1

  公开（公告）日：2011-12-22

  The present application relates to perfume raw materials, perfume delivery systems and consumer products comprising such perfume raw materials and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials and compositions, including the delivery systems, disclosed herein expand the perfume communities' options as such perfume raw materials can provide variations on character and such compositions can provide desired odor profiles.

  本申请涉及香水原料、香水传递系统和包含这种香水原料和/或这种香水传递系统的消费者产品，以及制造和使用这种香水原料、香水传递系统和消费者产品的过程。本文所披露的香水原料和配方，包括传递系统，在香水社区的选择方面提供了更多选项，因为这些香水原料可以提供不同的特性变化，这些配方可以提供所需的气味特征。
• NONSTEROIDAL COMPOUNDS USEFUL AS MODULATORS OF GLUCOCORTICOID RECEPTOR AP-1 AND/OR NF-KAPPAB ACITIVITY AND USE THEREOF
  申请人：Dhar T.G. Murali

  公开号：US20110263494A1

  公开（公告）日：2011-10-27

  Disclosed are compounds of Formula (I) wherein: one of A and D is —N— and the other of A and D is —C—; or enantiomers, diastereomers, or pharmaceutically-acceptable salts thereof. Also disclosed are methods of using such compounds to modulate the function of glucocorticoid receptor activity and pharmaceutical compositions comprising such compounds.

  公开的是具有以下结构的化合物（I）：其中：A和D中的一个是—N—，另一个是—C—；或其对映体、非对映体异构体或药用盐。还公开了使用这些化合物调节糖皮质激素受体活性的方法和包含这些化合物的药物组合物。
• [EN] USE OF BIOMARKERS FOR PREDICTING CLINICAL SENSITIVITY TO CANCER TREATMENT<br/>[FR] UTILISATION DE BIOMARQUEURS PERMETTANT DE PRÉDIRE LA SENSIBILITÉ CLINIQUE POUR LE TRAITEMENT DU CANCER
  申请人：CELGENE CORP

  公开号：WO2016057503A1

  公开（公告）日：2016-04-14

  A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to a subject having cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula (I):

  一种识别可能对治疗化合物产生响应的患有癌症的受试者的方法，包括向患有癌症的受试者施用治疗化合物；从受试者获取样本；确定样本中生物标志物的水平；如果受试者样本中的生物标志物水平与生物标志物的参考水平相比发生变化，则诊断该受试者可能对治疗化合物产生响应；其中治疗化合物是一种式（I）的化合物。